AN2 Therapeutics (ANTX) Change in Accured Expenses (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Change in Accured Expenses of -$662000.0 for Q1 2026, down 61.07% year-over-year from -$1.7 million in Q1 2025, and down 1.38% quarter-over-quarter from -$653000.0 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Change in Accured Expenses (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Change in Accured Expenses for 6 consecutive years, with -$662000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 61.07% year-over-year to -$662000.0; the TTM figure through Mar 2026 stood at -$2.7 million (down 4449.18% YoY), while the FY2025 annual figure was -$2.4 million, down 2006.35% from the prior year.
- Change in Accured Expenses declined to -$662000.0 in Q1 2026 per ANTX's latest filing, from -$653000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.2 million in Q2 2023 and bottomed at -$3.6 million in Q3 2023.
- Historically, Change in Accured Expenses has averaged $9647.1 across 5 years, with a median of -$249000.0 in 2025.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 495.24% — and 2025, when it slumped 555.65%.
- AN2 Therapeutics' Change in Accured Expenses stood at $560000.0 in 2022, then soared by 225.36% to $1.8 million in 2023, then plunged by 126.56% to -$484000.0 in 2024, then sank by 34.92% to -$653000.0 in 2025, then slipped by 1.38% to -$662000.0 in 2026.
- Business Quant data shows ANTX's Change in Accured Expenses at -$662000.0 in Q1 2026, -$653000.0 in Q4 2025, and -$249000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | 482,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 482,000.00 |
| Mar 31, 2026 | -1.81 Mn |
| Dec 31, 2025 | -653,000.00 |
| Sep 30, 2025 | -249,000.00 |
| Jun 30, 2025 | -353,000.00 |
| Mar 31, 2025 | -1.15 Mn |
| Dec 31, 2024 | -434,000.00 |
| Sep 30, 2024 | 270,000.00 |
| Jun 30, 2024 | 845,000.00 |
| Mar 31, 2024 | -3.02 Mn |
| Dec 31, 2023 | 117,000.00 |
| Sep 30, 2023 | 121,000.00 |
| Jun 30, 2023 | 5.03 Mn |
| Mar 31, 2023 | -1.43 Mn |
| Dec 31, 2022 | 1.03 Mn |
| Sep 30, 2022 | 13,000.00 |
| Jun 30, 2022 | 1.26 Mn |
| Mar 31, 2022 | -581,000.00 |
| Dec 31, 2021 | -273,000.00 |
| Sep 30, 2021 | 295,000.00 |